Restoring a Single Brain Clock Reverses Aging Biomarkers and Extends Lifespan in Mice, Cell Study Finds
A Chinese research team has shown that timed doses of 3'-deoxyadenosine can amplify circadian rhythms in one hypothalamic nucleus, roll back epigenetic age, and extend lifespan in aged male mice.
Overview
A study published on April 2 in Cell reports that pharmacologically boosting circadian rhythm amplitude in a small cluster of hypothalamic neurons can reverse molecular markers of aging and extend lifespan in aged male mice. The work, led by Haijiao Zhao and colleagues at Beijing Normal University and the National Institute of Biological Sciences in Beijing, identifies the hypothalamic paraventricular nucleus (PVN) as what the authors call a “pharmacological node linking circadian amplitude to organismal aging.”
The finding adds to a growing body of evidence that the decline of circadian clock function with age is not merely a symptom of getting older but may actively drive the aging process.
What the Study Found
The researchers administered 3’-deoxyadenosine (3dA), a naturally occurring adenosine analogue, to aged male mice on a schedule optimized to the animals’ circadian phase. According to the PubMed listing of the study, this timed dosing regimen strengthened circadian amplitude specifically in PVN neurons, restored synchrony between the brain’s master clock and peripheral tissue clocks, and normalized hormonal rhythms including corticosterone, the mouse equivalent of the human stress hormone cortisol.
Transcriptomic, hormonal, and epigenetic profiling revealed robust increases in PVN circadian amplitude following the treatment. Critically, the intervention reduced epigenetic age as measured by DNA methylation clocks, one of the most widely accepted molecular indicators of biological aging, according to the paper published in Cell.
The treated mice also lived longer than untreated controls, though the authors have not yet released the precise magnitude of lifespan extension in publicly available summaries.
How It Works
The PVN sits just below the brain’s master circadian pacemaker, the suprachiasmatic nucleus (SCN), and serves as a relay that translates timing signals into hormonal output governing metabolism, stress responses, and immune function. As animals age, PVN clock amplitude weakens, degrading these downstream rhythms.
3dA appears to act through a protein called RuvB-like ATPase 2 (Ruvbl2). When the researchers knocked out Ruvbl2 specifically in PVN neurons, all of 3dA’s anti-aging benefits disappeared, establishing Ruvbl2 as genetically necessary for the compound’s effects, as reported by Cell. As an independent check, the team used chemogenetic tools to directly activate PVN neurons without any drug, and this alone reproduced the metabolic and physiological improvements seen with 3dA treatment.
A commentary in Nature Reviews Drug Discovery highlighted the study as evidence that “dialling up” the circadian clock could become a viable therapeutic strategy for age-related disease.
What We Don’t Know
Several important caveats temper the results. The study was conducted exclusively in male mice; whether the same intervention works in females remains untested. The specific lifespan extension figures have not been detailed in publicly available summaries, making it difficult to gauge the practical magnitude of the effect.
It is also unclear how 3dA would behave in humans, whose circadian architecture differs from that of nocturnal rodents. 3’-Deoxyadenosine is a known natural compound, but its safety profile at the doses and schedules used in this study has not been evaluated in people. The path from a mouse longevity experiment to a human therapeutic is long, and most compounds that extend rodent lifespan have failed to translate.
Context
The study arrives amid intensifying interest in the circadian system as a target for pharmacological intervention. Earlier this year, a Japanese team reported that an oral compound called Mic-628 could reset the circadian clock and cut simulated jet lag recovery nearly in half in mice, as previously reported by The Machine Herald. While Mic-628 targets the Period1 gene to shift clock phase, the new Cell study takes a different approach by amplifying clock amplitude in a specific brain region to combat aging itself.
Together, the two lines of research suggest that the mammalian circadian system may be more pharmacologically tractable than previously appreciated, with distinct molecular entry points for different therapeutic goals.